Razoxane is an inhibitor of Topo II.
ChEBI: Razoxane is a N-alkylpiperazine.
Razoxane is clinically active against angiogenesis and metastasis. Razoxane specifically inhibits topoisomerase II without inducing DNA strand breaks (topo II catalytic inhibitor). It is an antimitotic agent with immunosuppressive properties. Razoxane inhibits blood-borne and lymphatic metastases in different experimental models. Studies have shown th at razoxane inhibits specifically the vasculogenic mimicry of B16F10 melanoma cells.
Suspected human carcinogen producing leukemia and skin tumors. Moderately toxic by intraperitoneal route. Human effects: normocytic anemia and thrombocytopenia. Human mutation data reported. When heated to decomposition it emits toxic fumes of NOx.
Early treatment with Razoxane (30 mg/kg i.p. from day -2 to +14) shows a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation)[2].
| Animal Model: | Sprague-Dawley rats[2] |
| Dosage: | 30 mg/kg or 10 mg/kg per day |
| Administration: | Intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation |
| Result: | Resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor. |
